Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

M-2018-334 in Hematological Malignancies

NCT: NCT06225050 · RECRUITING

NCT IDNCT06225050
StatusRECRUITING
Start Date2026-08-21
Completion2029-02-28
SponsorMiltenyi Biomedicine GmbH (INDUSTRY)
First posted
Last updated

Brief Summary

This is a single-center, open-label, single-arm, pilot clinical study using TCRα/β and CD45RA depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation in 12 to 18 adult patients.

Frequently Asked Questions

What is M-2018-334 in Hematological Malignancies?

M-2018-334 in Hematological Malignancies is a clinical trial registered under NCT06225050. Current status: RECRUITING.

What is the status of NCT06225050?

The current status of NCT06225050 (M-2018-334 in Hematological Malignancies) is: RECRUITING.

When did M-2018-334 in Hematological Malignancies start?

M-2018-334 in Hematological Malignancies started on 2026-08-21.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑